Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding their personal holdings of the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing reports an increase in share interests for specific individuals following the re-investment of the dividend paid to shareholders on July 11, 2013. The transaction price was 1,752.9543 pence per Ordinary Share. Specific increases include:
- Sir Andrew Witty: 1,956 shares
- Lady C Witty (Connected Person): 1,493 shares
- Mr I W Whyte (Connected Person): 106 shares
- Mrs V A Whyte: No change reported
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory compliance notification regarding director shareholdings.
Investor Verification Points
- Verify the dividend reinvestment price of 1,752.9543 pence per share against market data for July 11, 2013.
- Confirm the total shareholding positions of Sir Andrew Witty and connected persons post-transaction.
- Review the company's Form 20-F for comprehensive financial results, as this 6-K contains no financial statements.